Aroa Biosurgery Limited
Aroa Biosurgery Limited
Your view on ARX.AX
Overview
What the company does, where it operates, and who runs it.
About Aroa Biosurgery Limited
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Brian Ward
- Headquarters
- 64 Richard Pearse Drive, Auckland, AU, NZ
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Brian Ward
- Headquarters
- 64 Richard Pearse Drive, Auckland, AU, NZ
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Aroa Biosurgery Limited, and the rating behind it. ARX.AX last traded at AUD 0.56, 62.4× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Aroa Biosurgery Limited. Starting points for Aroa Biosurgery Limited: P/E 62.4, EPS AUD 0.0091, beta 0.85 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Aroa Biosurgery Limited. Aroa Biosurgery Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Aroa Biosurgery Limited. Trailing twelve-month EPS for Aroa Biosurgery Limited stands at AUD 0.0091. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Aroa Biosurgery Limited. Aroa Biosurgery Limited has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Aroa Biosurgery Limited valued side by side against its closest peers. Aroa Biosurgery Limited is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Aroa Biosurgery Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Aroa Biosurgery Limited executives and directors. Shares of Aroa Biosurgery Limited have traded between AUD 0.49 and AUD 0.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Aroa Biosurgery Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Aroa Biosurgery Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Aroa Biosurgery Limited. Coverage tracks Aroa Biosurgery Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.